Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Hospices Civils de Lyon (HCL) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
144.6 rhumatos / 100 000 hab. — département bien doté
7 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
10
10 articles ont été cités au moins 10fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
861
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
32
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
10
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Louis Pradel
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Prognostic factors in interstitial lung disease-associated pulmonary hypertension: data from the HYPID cohort and the French Pulmonary Hypertension Registry
2026ArticleEuropean Respiratory Journal
Development and validation of the FIP-Score for the screening of FIP1L1::PDGFRA-associated hypereosinophilic syndrome
2025ArticleJournal of Allergy and Clinical Immunology: In Practice
Pulmonary function test results are correlated with 6-minute walk distance, distance-saturation product, and 6-minute walk work in patients with lymphangioleiomyomatosis
2024ArticleRespiratory Medicine and Research
Bioreactance assessment of cardiac output lacks reliability for the follow-up of patients with pulmonary hypertension
2024ArticlePLoS ONE
Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
2024ArticleFrontiers in Medicine
Upfront triple therapy with parenteral prostanoid as a bridge to balloon pulmonary angioplasty in severe chronic thromboembolic pulmonary hypertension
2024ArticleERJ Open Research
French recommendations for the diagnosis and management of lymphangioleiomyomatosis
2023ArticleRespiratory Medicine and Research
COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study
2022ArticleAmerican Journal of Respiratory and Critical Care Medicine
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL LOUIS PRADEL - HCL
28 AV DOYEN LEPINE, 69677 BRON CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The European respiratory journal · 2021
In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing phenotype (PF-ILD) may develop, but information on the frequency and characteristics of this population outside clinical trials is lacking.We assessed the characteristics and outcomes of patients with PF-ILD other than idiopathic pulmonary fibrosis (IPF) in a real-world, single-centre clinical cohort. The files of all consecutive adult patients with fibrosing ILD (2010–2017) were examined retrospectively for pre-defined criteria of ≥10% fibrosis on high-resolution computed tomography and progressive disease during overlapping windows of 2 years. Baseline was defined as the date disease progression was identified. Patients receiving nintedanib or pirfenidone were censored from survival and progression analyses.In total, 1395 patients were screened; 617 had ILD other than IPF or combined pulmonary fibrosis and emphysema, and 168 had progressive fibrosing phenotypes. In 165 evaluable patients, median age was 61 years; 57% were female. Baseline mean forced vital capacity (FVC) was 74±22% predicted. Median duration of follow-up was 46.2 months. Annualised FVC decline during the first year was estimated at 136±328 mL using a linear mixed model. Overall survival was 83% at 3 years and 72% at 5 years. Using multivariate Cox regression analysis, mortality was significantly associated with relative FVC decline ≥10% in the previous 24 months (p<0.05), age ≥50 years (p<0.01) and diagnosis subgroup (p<0.01).In this cohort of patients with PF-ILD not receiving antifibrotic therapy, the disease followed a course characterised by continued decline in lung function, which predicted mortality.
Journal of clinical medicine · 2021
Variable patterns of disease progression are typically observed in patients with idiopathic pulmonary fibrosis (IPF). We sought to determine the prognostic capacity of blood cell count indexes, derived from routine complete blood cell (CBC) count, in a cohort of IPF patients. The neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) were calculated at baseline in a consecutive series of 82 IPF patients followed for four years. After adjusting for age, gender, body mass index, smoking status, and disease stage, only the AISI was significantly associated with mortality (HR 1.0013, 95% CI 1.0003–1.0023, p = 0.015). Patients with AISI <434 and ≥434 had a median survival from the diagnosis of 35.3 ± 15.2 and 26.6 ± 16.3 months (p = 0.015), and a four-year survival rate of 54% and 34%, respectively. The AISI, easily derivable from routine laboratory tests, is independently associated with mortality in patients with IPF. Prospective studies in larger cohorts are required to confirm this association.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Pulmonology · 2025 · Journal Article
Diesler R, Gallay L, Uzunhan Y, Borie R, et al.
Annals of medicine and surgery (2012) · 2025 · Journal Article
Ahmad K, Ali M, Muhammad S, Daoud A, et al.
Respiratory medicine and research · 2024 · Journal Article
Diesler R, Cottin V, Gallien Y, Turquier S, et al.
Frontiers in medicine · 2024 · Journal Article
Desaintjean C, Ahmad K, Traclet J, Gerfaud-Valentin M, et al.
Respiratory medicine and research · 2023 · Review
Provost M, Mornex JF, Nasser M, Zeghmar S, et al.
Respiratory medicine and research · 2023 · Practice Guideline
Cottin V, Blanchard E, Kerjouan M, Lazor R, et al.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2023 · Journal Article
Manubolu VS, Mao S, Kinninger A, Dahal S, et al.
The European respiratory journal · 2021 · Journal Article
Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2021 · Journal Article
Chauvelot L, Gamondes D, Berthiller J, Nieves A, et al.
Frontiers in medicine · 2019 · Journal Article
Fernandes L, Nasser M, Ahmad K, Cottin V
Respiratory medicine · 2017 · Letter
Ahmad K, Cottin V
Respiratory medicine · 2017 · Journal Article
Ahmad K, Barba T, Gamondes D, Ginoux M, et al.
JPMA. The Journal of the Pakistan Medical Association · 2015 · Journal Article
Khan I, Jawaid A, Ahmad K, Noordin S
JAAD case reports · 2019 · Case Reports
Tierney E, Kirthi S, Ramsay B, Ahmad K
JAAD case reports · 2017 · Case Reports
Lynch M, Roche L, Horgan M, Ahmad K, et al.
Journal of clinical medicine · 2025 · Journal Article
Petitgrand L, Ahmad K, Gamondès D, Diesler R, et al.
Clinical and experimental rheumatology · 2021 · Case Reports
Merveilleux du Vignaux C, Ahmad K, Tantot J, Rouach B, et al.
The European respiratory journal · 2026 · Journal Article
Diesler R, Turquier S, Reynaud-Gaubert M, Lestelle F, et al.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2019 · Letter
Bravos E, Cottin V, Dauphin C, Bouvaist H, et al.
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2022 · Journal Article
Nisar S, Ahmad K, Palan J, Pandit H, et al.
Respiration; international review of thoracic diseases · 2020 · Journal Article
Aussedat PH, Chebib N, Ahmad K, Glerant JC, et al.
Irish journal of medical science · 2021 · Journal Article
Griffin L, Boggs J, Ramsay B, Hackett C, et al.
The British journal of dermatology · 2007 · Journal Article
Ahmad K, Rogers S
Journal of clinical medicine · 2021 · Journal Article
Zinellu A, Collu C, Nasser M, Paliogiannis P, et al.
Annals of the American Thoracic Society · 2021 · Journal Article
Lacoste-Palasset T, Chaumais MC, Weatherald J, Savale L, et al.
The European respiratory journal · 2021 · Letter
Justet A, Klay D, Porcher R, Cottin V, et al.
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2022 · Journal Article
Nisar S, Ahmad K, Palan J, Pandit H, et al.
Experimental and clinical cardiology · 2008 · Case Reports
Nagajothi N, Mejia JA, Raghunathan K, Velazquez-Cecena JL, et al.